Dudediligence.

Vistagen Therapeutics, Inc

VTGNNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$183,000Sep ’24$234,000Dec ’24−$15,000Mar ’25$244,000Jun ’25$258,000Sep ’25$303,000Dec ’25$465,000Mar ’26$1.5MJun ’26
Net income, by quarter
−$13.0MSep ’24−$14.1MDec ’24−$13.6MMar ’25−$15.1MJun ’25−$19.4MSep ’25−$18.9MDec ’25−$16.3MMar ’26−$13.0MJun ’26
Fiscal years, by the month each ended
LineMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue$1.1Mnone on file$1.1M$486,000$1.3M
Operating income−$47.8M−$59.3M−$33.0M−$56.0M−$72.1M
Net income−$47.8M−$59.2M−$29.4M−$51.4M−$69.7M
Operating cash flow−$45.3M−$49.7M−$25.8M−$42.1M−$66.4M
Free cash flow−$45.5M−$50.2M−$25.8Mnone on filenone on file
Cash$68.1M$16.6M$119.2M$67.1M$30.8M
Shares outstanding6.9M7.3M27.0M29.0M39.6M